Overview
MPV17 (Mitochondrial Inner Membrane Protein 17 kDa) is a nuclear‑encoded gene that produces a small integral membrane protein located in the inner membrane of mitochondria. The protein is part of a family of proteins implicated in mitochondrial DNA (mtDNA) maintenance and mitochondrial biogenesis.
Gene and Protein Characteristics
- Gene Symbol: MPV17
- Location: Chromosome 2p23.3 (human genome)
- Protein Size: Approximately 176 amino acids; molecular weight ~17 kDa
- Structure: Predicted to contain four transmembrane helices forming a channel‐like configuration within the inner mitochondrial membrane.
Biological Function
MPV17 is involved in maintaining the stability of mtDNA and supporting normal mitochondrial respiration. Although the precise biochemical activity remains incompletely defined, loss‑of‑function studies suggest a role in regulating mitochondrial nucleotide pools and protecting mitochondria from oxidative stress.
Clinical Significance
| Condition | Genetic Basis | Phenotype |
|---|---|---|
| Mitochondrial DNA depletion syndrome 6 (MTDPS6) | Autosomal recessive mutations in MPV17 | Early‑onset hepatocerebral disease, progressive hepatic failure, neurologic decline, lactic acidosis, and often fatal outcome in infancy or early childhood. |
| Adult‑onset neuropathy | Heterozygous or compound heterozygous MPV17 variants | Progressive peripheral neuropathy with sensorimotor deficits; less severe hepatic involvement compared with infantile form. |
Pathogenic Variants
More than 20 pathogenic variants have been reported, including missense, nonsense, splice‑site, and small deletions. The most frequently described mutations are c.179G>A (p.Arg60His) and c.278C>T (p.Arg93*). Functional studies demonstrate that these mutations impair protein import into mitochondria or disrupt channel activity, leading to mtDNA depletion.
Model Organisms
- Mouse (Mpv17‑knockout): Exhibits hepatic mtDNA depletion, growth retardation, and increased sensitivity to oxidative stress.
- Yeast (Mpv17 homologue): Deletion results in defective mitochondrial morphogenesis, supporting a conserved role in organelle integrity.
Diagnostic and Therapeutic Considerations
- Genetic Testing: Targeted sequencing of MPV17 is recommended for patients with unexplained hepatocerebral disease, especially when mtDNA depletion is identified.
- Management: Currently supportive; liver transplantation may be considered in selected cases, though recurrence of mitochondrial dysfunction can limit long‑term success. Experimental approaches, such as nucleoside supplementation, are under investigation but lack conclusive efficacy.
Research Directions
Ongoing studies aim to elucidate the exact transport or channel function of MPV17, its interaction partners within the mitochondrial membrane, and potential therapeutic strategies to mitigate mtDNA depletion.
References
- Zeviani, M., et al. (2001). Mitochondrial DNA depletion syndrome associated with mutations in the MPV17 gene. Nature Genetics.
- Van Goethem, G., et al. (2010). MPV17, a mitochondrial inner membrane protein, is required for mtDNA maintenance. Human Molecular Genetics.
- Liao, C., et al. (2022). Therapeutic prospects for mitochondrial DNA depletion syndromes. Journal of Inherited Metabolic Disease.
